Palisade Bio's Recent Patent Achievement
Palisade Bio, Inc. is making significant strides in the biopharmaceutical landscape with its lead product candidate, PALI-2108. This innovative PDE4 inhibitor is uniquely designed to target the terminal ileum and colon specifically for conditions such as fibrostenotic Crohn’s disease (FSCD) and ulcerative colitis (UC). The need for effective therapies in this area is substantial, making PALI-2108 a vital product aimed at fulfilling unmet medical needs.
The Market Landscape
Inflammatory Bowel Disease represents a major segment of the healthcare market, particularly in China, with revenue forecasts approaching $1 billion by 2030. This potential creates an exciting opportunity for companies like Palisade Bio to develop and commercialize treatments that can significantly improve patients' quality of life.
Patent Notice of Allowance in China
Recently, Palisade Bio announced that it received a Notice of Allowance from the China National Intellectual Property Administration for a patent covering PALI-2108. This patent is titled "Gut Microbiota-Activated PDE4 Inhibitor Prodrug" and it encompasses claims about the composition of matter for PALI-2108 in China. The base patent term is currently set to extend until 2045, which may be further extended based on the time required for regulatory approval.
Importance of Intellectual Property
CEO J.D. Finley emphasized the importance of a robust intellectual property portfolio for PALI-2108, stating, "Strengthening the global intellectual property portfolio around PALI-2108 remains a priority as we continue advancing this first-in-class therapy for FSCD and UC." The receipt of this patent allowance in China enhances the company’s ability to maintain long-term value in a rapidly expanding market.
Clinical Trials Progress
Currently, Palisade Bio is actively evaluating PALI-2108 in a Phase 1b/2a clinical trial aimed at treating FSCD and UC. The clinical trial's progress is pivotal, as successful outcomes could result in significant value milestones for the company.
Future Milestones
Palisade’s clinical and strategic objectives revolve around achieving multiple near-term milestones and data readouts over the next 12 to 18 months. Finley expressed confidence in PALI-2108's potential: "Each of these milestones, if successful, would represent a major value inflection point for the company and our shareholders." The development plans signify a hopeful outlook for both the company and its investors.
About Palisade Bio
Palisade Bio is dedicated to developing groundbreaking therapeutics for patients suffering from autoimmune, inflammatory, and fibrotic diseases. With a focus on targeted treatments, Palisade aims to revolutionize the existing medical frameworks and improve outcomes for patients.
Frequently Asked Questions
What is PALI-2108?
PALI-2108 is a PDE4 inhibitor specifically designed for treating fibrostenotic Crohn’s disease and ulcerative colitis, targeting the terminal ileum and colon.
What recent achievement has Palisade Bio attained?
Palisade Bio received a Notice of Allowance for a patent related to PALI-2108 from the China National Intellectual Property Administration.
What is the potential market for inflammatory bowel disease treatments?
The market for inflammatory bowel disease treatments, particularly in China, is projected to reach nearly $1 billion by 2030.
What clinical trials is Palisade Bio currently conducting?
The company is conducting a Phase 1b/2a clinical trial evaluating PALI-2108 for its efficacy and safety in patients with FSCD and UC.
How does Palisade Bio plan to use its patent allowance?
The patent allowance will support the company in safeguarding the long-term value and market position of PALI-2108 in a fast-growing pharmaceutical landscape.
